TPO and autoimmune thrombocytopenic purpura: Eltrombopag (ELT), a thrombopoietin receptor agonist (TPO-RA), is the first guideline-recommended second-line treatment for pediatric ITP (Neunert et al., 2019; Provan et al., 2019).